Five day moxifloxacin therapy compared with 7 day clarithromycin therapy for the treatment of acute exacerbations of chronic bronchitis

Journal of Antimicrobial Chemotherapy

Volumn 44, Issue 4, 1999, Pages 501-513

  Wilson, Robert ^a,j   Kubin, Rolf ^b   Ballin, Ian ^c   Deppermann, Karl Matthias ^d   Bassaris, Harry P ^e   Leophonte, Paul ^f   Schreurs, Ad J M ^g   Torres, Antonio ^h   Sommerauer, Bernd ⁱ  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

^b Bayer plc UK   (United Kingdom)

^c Pendlebury Children's Hospital   (United Kingdom)

^d Pneumologische Klinik   (Germany)

^e UNIVERSITY HOSPITAL OF PATRAS   (Greece)

^f CHU RANGUEIL   (France)

^g Onze Lieve Vrouwe Gasthuis ^*  (Netherlands)

^h HOSPITAL CLÍNIC   (Spain)

ⁱ Bayer Pharma   (France)

^j NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CLARITHROMYCIN; MOXIFLOXACIN;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; ASTHMA; CHRONIC BRONCHITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; FEMALE; FOLLOW UP; HAEMOPHILUS INFLUENZAE; HEADACHE; HUMAN; JAUNDICE; MAJOR CLINICAL STUDY; MALE; MORAXELLA CATARRHALIS; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; PNEUMONIA; RANDOMIZED CONTROLLED TRIAL; SPUTUM; STREPTOCOCCUS PNEUMONIAE; TASTE DISORDER; TIME; TREATMENT OUTCOME; URTICARIA; VERTIGO;

ACUTE DISEASE; ADULT; AGED; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; AZA COMPOUNDS; BACTERIA; BRONCHITIS; DOUBLE-BLIND METHOD; DRUG RESISTANCE, MICROBIAL; ERYTHROMYCIN; FEMALE; FLUOROQUINOLONES; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUINOLINES;

EID: 0032835722     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/44.4.501     Document Type: Article

References (38)

1. American Thoracic Society. (1995). Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine 152, Suppl., S77-121.
2. Wilson, R., Tillotson, G. & Ball, P. (1996). Clinical studies in chronic bronchitis: a need for better definition and classification of severity. Journal of Antimicrobial Chemotherapy 37, 205-8.
3. Chodosh, S. (1990). Quinolones in acute bacterial exacerbations of chronic bronchitis. In The New Generation of Quinolones (Siporin, C., Heifetz, C. L. & Domagala, J. M., Eds), pp. 249-76. Marcel Dekker, Inc., New York, NY.
4. Anthonisen, N. R., Manfreda, J., Warren, C. P. W., Hershfield, E. S., Harding, G. K. & Nelson, N. A. (1987). Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Annals of Internal Medicine 106, 196-204.
5. Saint, S., Bent, S., Vittinghoff, E. & Grady, D. (1995). Antibiotics in chronic obstructive pulmonary disease exacerbations: a meta-analysis. Journal of the American Medical Association 273, 957-60.
6. Felmingham, D. & Grüneberg, R. N. (1996). A multicentre collaborative study of the antimicrobial susceptibility of community-acquired, lower respiratory tract pathogens 1992-1993: the Alexander Project. Journal of Antimicrobial Chemotherapy 38, Suppl. A, 1-57.
7. Thomsberry, C., Ogilvie, P., Kahn, J. & Mauriz, Y. (1997). Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996-1997 respiratory season. The Laboratory Investigator Group. Diagnostics in Microbiology and Infectious Disease 29, 249-57.
8. Friedland, I. R. & McCracken, G. H. (1994). Management of infections caused by antibiotic resistant Streptococcus pneumoniae. New England Journal of Medicine 331, 377-82.
9. Latorre, C., Juncosa, T. & Sanfeliu, I. (1985). Antibiotic resistance and serotypes of 100 Streptococcus pneumoniae strains isolated in a children's hospital in Barcelona, Spain. Antimicrobial Agents and Chemotherapy 28, 357-9.
10. Marton, A., Gulyas, M., Munoz, R. & Tomasz, A. (1991). Extremely high incidence of antibiotic resistance in clinical isolates of Streptococcus pneumoniae in Hungary. Journal of Infectious Diseases 163, 542-8.
11. Reinert, R. R., Queck, A., Kaufhold, A., Kresken, M. & Lütticken, R. (1995). Antimicrobial resistance and type distribution of Streptococus pneumoniae isolates causing systemic infections in Germany, 1992-1994. Clinical Infectious Diseases 21, 1398-401.
12. Felmingham, D., Robbins, M. J., Tesfaslasie, Y., Harding, I., Shrimpton, S. & Grüneberg, R. N. (1998). Antimicrobial susceptibility of community-acquired lower respiratory tract bacterial pathogens isolated in the UK during the 1995-1996 cold season. Journal of Antimicrobial Chemotherapy 41, 411-5.
13. Wise, R. & Andrews, J. M. (1998). Local surveillance of antimicrobial resistance. Synercid Resistance Surveillance Group. Lancet 352, 657-8.
14. Mason, E. O. & Kaplan, S. L. (1995). Penicillin-resistant pneumococci in the United States. Pediatric Infectious Disease Journal 14, 1017-8.
15. Felmingham, D., Robbins, M. J., Dencer, C., Nathwani, A. & Grüneberg, R. N. (1996). Antimicrobial susceptibility of community-acquired bacterial lower respiratory tract pathogens. Journal of Antimicrobial Chemotherapy 38, 747-51.
16. Dalhoff, A., Petersen, U. & Endermann, R. (1996). In vitro activity of BAY 12-8039, a new 8-methoxyquinolone. Chemotherapy 42, 410-25.
17. MacGowan, A. P., Bowker, K. E., Holt, H. A., Wootton, M. & Reeves, D. S. (1997). BAY 12-8039, a new 8-methoxy-quinolone: comparative in-vitro activity with nine other antimicrobials against anaerobic bacteria. Journal of Antimicrobial Chemotherapy 40, 503-9.
18. Woodcock, J. M., Andrews, J. M., Boswell, F. J., Brenwald, N. P. & Wise, R. (1997). In vitro activity of BAY 12-8039, a new fluoroquinolone. Antimicrobial Agents and Chemotherapy 41, 101-6.
19. Robson, H. G., Tremblay, J.-F., Loo, V. G., Lavallee, J. & McAlear, D. (1997). Comparative in-vitro activity of trovafloxacin, BAY 12-8039 and clinafloxacin against penicillin-intermediate and -resistant Streptococcus pneumoniae. In Program and Abstracts of the Thirty-Seventh Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, 1997. Abstract F135, p. 169. American Society for Microbiology, Washington, DC.
20. Visalli, M. A., Jacobs, M. R. & Appelbaum, P. C. (1997). Antineumococcal activity of BAY 12-8039, a new quinolone, compared with activities of three other quinolones and four oral β-lactams. Antimicrobial Agents and Chemotherapy 41, 2786-9.
21. Stass, H., Dalhoff, A., Kubitza, D. & Schühly, U. (1998) Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxyquinolone, administered to healthy subjects. Antimicrobial Agents and Chemotherapy 42, 2060-5.
22. Andrews, J., Honeybourne, D., Jevons, G. & Wise, R. (1998). Penetration of moxifloxacin into bronchial mucosa, epithelial lining fluid and alveolar macrophages following a single 400 mg oral dose. In Program and Abstracts of the Thirty-Eighth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, USA, 1998. Abstract A29, p. 9. American Society for Microbiology, Washington, DC.
23. Siafakas, N. M., Vermeire, P., Pride, N. B., Paoletti, P., Gibson, J., Howard, P. et al. (1995). Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. European Respiratory Journal 8, 1398-420.
24. Appelbaum, P. C. (1996). Epidemiology and in vitro susceptibility of drug-resistant Streptococcus pneumoniae. Pediatric Infectious Disease Journal 15, 932-4.
25. Doern, G. V., Brueggemann, A., Holley, H. P. & Rauch, A. M. (1996). Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: results of a 30-center national surveillance study. Antimicrobial Agents and Chemotherapy 40, 1208-13.
26. Cazzola, M., Vinciguerra, A., Beghi, G. F., Paizis, G., Giura, R., Madonini, V. et al. (1995). Comparative evaluation of the clinical and microbiological efficacy of co-amoxiclav versus cefixime or ciprofloxacin in bacterial exacerbation of chronic bronchitis. Journal of Chemotherapy 7, 432-41.
27. Chodosh S., Lakshminarayan, S., Swarz, H. & Breisch, S. (1998). Efficacy and safety of a 10-day course of 400 or 600 milligrams of grepafloxacin once daily for treatment of acute bacterial exacerbations of chronic bronchitis: comparison with a 10-day course of 500 milligrams of ciprofloxacin twice daily. Antimicrobial Agents and Chemotherapy 42, 114-20.
28. Periti, P., Novelli, A., Schildwachter, G., Schmidt-Gayk, H., Ryo, Y. & Zuck, P. (1990). Efficacy and tolerance of cefpodoxime proxetil compared with co-amoxiclav in the treatment of exacerbations of chronic bronchitis. Journal of Antimicrobial Chemotherapy 26, Suppl. E, 63-9.
29. Rademaker, C. M. A., Sips, A. P., Beumer, H. M., Hoepelman, I. M., Overbeek, B. P., Möllers, M. J. et al. (1990). A double-blind comparison of low-dose ofloxacin and amoxycillin-clavulanic acid in acute exacerbations of chronic bronchitis. Journal of Antimicrobial Chemotherapy 26, Suppl. D, 75-81.
30. Ziering, W. & McElvaine, P. (1998). Randomized comparison of once-daily ceftibuten and twice-daily clarithromycin in the treatment of acute exacerbations of chronic bronchitis. Infection 26, 68-75.
31. Ball, P., Harris, J. M., Lowson, D., Tillotson, G. & Wilson, R. (1995). Acute infective exacerbations of chronic bronchitis. Quarterly Journal of Medicine 88, 61-8.
32. Wilson, R. (1995). Outcome predictors in bronchitis. Chest 108, Suppl., 53S-7S.
33. Sufarlan, A. W., Zainudin, B. M. Z., Pit, S. & Ishak, I. (1995). Causative organisms in acute exacerbation of chronic airways disease and response to ofloxacin therapy. Drugs 49, Suppl. 2, 442-5.
34. Langan, C., Clecner, B., Cazzola, C. M., Brambilla, C., Holmes, C. Y. & Staley, H. (1998). Short-course cefuroxime axetil therapy in the treatment of acute exacerbations of chronic bronchitis. International Journal of Clinical Practice 52, 289-97.
35. Monso, E., Ruiz, J., Rosell, A., Manterola, J., Fiz, J., Morera, J. et al. (1995). Bacterial infection in chronic obstructive pulmonary disease. A study of stable and exacerbated outpatients using the protected specimen brush. American Journal of Respiratory Critical Care Medicine 152, 1316-20.
36. Rutman, A., Dowling, R., Wills, P., Feldman, C., Cole, P. J. & Wilson, R. (1998). Effect of dirithromycin on Haemophilus influenzae infection of the respiratory mucosa. Antimicrobial Agents and Chemotherapy 42, 772-8.
37. Ferguson, J. (1995). Fluoroquinolone photosensitization: a review of clinical and laboratory studies. Photochemistry and Photobiology 62, 954-8.
38. Ferguson, J., Al-Ajmi, H., Kubin, R., Daggett, S. & Saggu, P. S. (1998). A double-blind, placebo and Iomefloxacin controlled human volunteer study to determine the photosensitising potential of oral moxifloxacin (BAY 12-8039). In Program and Abstracts of the Eighth International Congress on Infectious Diseases, Boston, USA, 1998. Abstract 59.001, p. 197. International Society for Infectious Diseases.